Webinar: Setting up a pharmacovigilance system in Europe. Where to start? What to consider?
Setting up a pharmacovigilance system is not as straightforward an answer as it may sound. There are many aspects to consider, which can seem complicated, especially when you must focus on developing your product. In the first part of this webinar, our experts lay out all the steps necessary to set up a system and discuss best practices in critical areas.
In the webinar’s second part, we dive deeply into actual best practices to overcome day-to-day challenges. Our experts welcome questions from real-world challenges to help you meet pharmacovigilance requirements efficiently. Whether expanding to the EU or bringing your first product to market here, join us if you’re planning to establish a pharmacovigilance system in Europe and set yourself up for success.
Thinking how to ensure drug safety?
Let’s talk how we can team up to optimize your pharmacovigilance activities in Europe.
Who Should Attend?
Professionals from drug safety:
- Global QPPVs / Deputies
- QPPV Office managers
- Heads of Pharmacovigilance
- Heads of Pharmacovigilance Technologies
- Drug Safety Managers and Leaders
Duration: 1 hour.
Speakers:
- Martijn van de Leur, Head of Global Pharmacovigilance
- Olga Asimaki, International QPPV / Head of Medical Information
- Albert Bekfi, Head of Pharmacovigilance Operations
Martijn van de Leur
Head of Global Pharmacovigilance
Sign up for the webinar. Stay up to date.
Other content that might interest you:
National differences for Pharmacovigilance in Europe
Join our webinar on “Navigating National Differences in Setting up a Pharmacovigilance System in Europe.” 🇪🇺 💊
Oncology trials in a shifting economical and geopolitical landscape
Webinar: Oncology trials in a shifting economical and geopolitical landscape The pharmaceutical and biotech fields are spinning around, seeking to...
How to Avoid Delays in Your Early Phase Oncology Trial?
Webinar: How to Avoid Delays in Your Early Phase Oncology Trial? Many things can go array in your early phase oncology trials, from protocol...
